The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Research Grant, 2010Symptoms and Side Effects of LRRK2 Mutation Carriers and Assessment of Factors Influencing LRRK2-related PD Expression
Objective/Rationale:
By incorporating our Spanish LRRK2 cohort with G2019S and R1441G mutations into the existing LRRK2 Cohort Consortium (L2CC) of people of Ashkenazi Jewish and North African Arab... -
MJFF Research Grant, 2010Development of Selective LRRK2 Inhibitors
Objective/Rationale:
LRRK2 kinase has been implicated as a potential therapeutic target for the treatment of Parkinson’s disease. The goal of our project is to make experimental drugs to test whether... -
Therapeutics Development Initiative, 2010Development of a Zinc Finger Protein Therapeutic for the Potential Treatment of Parkinson's Disease
Objective/Rationale:
Engineered zinc finger protein transcription factors (ZFP TFs) can be designed to specifically increase the level of a therapeutically important protein from its native gene in a... -
Biomarkers, 2010Optimizing Biochemical Biomarkers for PD Research
Objective/Rationale:
A biochemical biomarker is a chemical in bodily fluids (e.g. blood, cerebrospinal fluid, urine, etc.) that may be helpful in detecting Parkinson’s disease (PD) or in measuring the... -
Target Validation, 2010VEGF-B - A New Neurotrophic Factor for Treatment for Parkinson's Disease
Objective/Rationale:
We discovered that the vascular endothelial growth factor, VEGF-B, acts as a natural response of brain cells to a neurotoxin that produces Parkinson’s disease in pre-clinical... -
Target Validation, 2010mTORC1 as a Target for the Treatment of Levodopa-induced Dyskinesia
Objective/Rationale:
The choreic and dystonic movements, or dyskinesia, which develop in response to prolonged treatment with levodopa, represent one of the major limitations to the current therapy...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.